T0	Outcomes 196 215	efficacy and safety
T1	Outcomes 695 723	end-point was the difference
T2	Outcomes 768 982	end-points were differences in daily mean: (i) voiding frequency at 4 and 8Â weeks; (ii) urgency frequency; (iii) urgency incontinence frequency; (iv) incontinence frequency; (v) nocturia frequency; and (vi) quality
T3	Outcomes 998 1117	The variables for safety analysis were adverse events, vital signs, residual urine volume and clinical laboratory tests
T4	Outcomes 1257 1268	differences